All News

With the acceptance of the new drug application and granting priority review, the target action date is August 12, 2025.

App notifications can be effected by various notification focuses, software updates, or connecting hardware, such as car audio or wireless earphones.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic, discusses key benefits of incorporating biosimilars into a health system's formulary.

Karissa Kim, PharmD, BCPS, BCACP, discusses the main challenges pharmacists face in assessing and addressing patients’ health literacy levels.

The prevalence of high blood pressure is highest in Mississippi at 40.2% compared with the lowest in Colorado at 24.6%.

Researchers conducted a population-based study of women in Korea to analyze the association between age at menopause and incidence of type 2 diabetes.

ADI-001 is an investigation allogeneic gamma delta chimeric antigen receptor T cell therapy that targets CD20 for the treatment of a variety of autoimmune diseases.

Primary hyperoxaluria type 1 (PH1) is a rare genetic condition that affects the kidney, bladder, or urinary tract, and indicates high levels of oxalates in the urine.

Scott Nelson, PharmD, MS, FAMIA, ACHIP, joined Drug Topics to discuss the 2025 Pharmacy Forecast and AI’s role in the future of pharmacy practice.

Children with type 1 diabetes who watched educational videos and played games had improved glycemic control and quality of life.

As a new presidential administration begins to take shape, experts are curious about its promises of potential PBM reform within the pharmacy benefits industry.

In a systematic review, researchers explored how biofeedback impacted rehabilitation in patients experiencing chronic pain disorders.

The therapy is now the first and only FDA-approved treatment that maintains vision with fewer treatments compared to standard-of-care injections.

Sodium-glucose cotransporter 2 inhibitors are more cardioprotective in older adults and glucagon-like peptide-1 receptor agonists for younger patients.

Rebecca Lahrman, PharmD, MS, BCACP discusses her time as a preceptor and what she learned from the experience.

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed tactics and challenges health-system pharmacy encounters within the distribution of patient benefits.

Researchers addressed the factors leading to and the rates of discontinuation and reinitiation of GLP-1 RAs among adults with obesity.

The drug will be made available in the second quarter of 2025.

Approximately 29% of patients were also more likely to refill their medication, leading investigators to consider an association between medication adherence.

Erin Fox, PharmD, MHA, BCPS, FASHP, joined Drug Topics to explore ultra-high-cost drugs and pharmacists’ role in managing patients’ prescription regimens.

In a phase 1b/2a clinical trial, investigators evaluated the once weekly subcutaneous drug for safety, tolerability, pharmacokinetics, and proof-of-concept.

Taking once-weekly subcutaneous semaglutide does not increase depression symptoms or suicidal ideation in patients with obesity.

In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.

There is no standard way to define resilience in adolescent patients with type 1 diabetes, though many studies see resilience as an ability or process.

Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.

A survey conducted by 3 Axis Advisors revealed potential impacts of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.